Inactivation of the Prolyl Isomerase Pin1 Sensitizes BRCA1-Proficient Breast Cancer to PARP Inhibition

PARP inhibitor monotherapies are effective to treat patients with breast, ovary, prostate, and pancreatic cancer with BRCA1 mutations, but not to the much more frequent BRCA wild-type cancers. Searching for strategies that would extend the use of PARP inhibitors to BRCA1-proficient tumors, we found...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cancer Res
Glavni autori: Luo, Man-Li, Zheng, Fang, Chen, Wenying, Liang, Zhi-Mei, Chandramouly, Gurushankar, Tan, Jianan, Willis, Nicholas A., Chen, Chun-Hau, Taveira, Mateus de Oliveira, Zhou, Xiao Zhen, Lu, Kun Ping, Scully, Ralph, Wulf, Gerburg M., Hu, Hai
Format: Artigo
Jezik:Inglês
Izdano: 2020
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7755124/
https://ncbi.nlm.nih.gov/pubmed/32193285
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-19-2739
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items